IQ-DAA is under clinical development by IQ Therapeutics and currently in Phase I for Anthrax. According to GlobalData, Phase I drugs for Anthrax have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IQ-DAA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IQ-DAA is under development for the treatment of anthrax. It is administered intravenously. It is developed using the cloning the human response technology. The technology results in antibodies which have been matured and optimized by the human immune system and are therefore most suitable for fighting infectious diseases in humans. It is a dual antibody approach using a combination of two monoclonal antibodies neutralizing the lethal toxin produced by Bacillus anthracis targeting anthrax toxin lethal factor (LF).
IQ Therapeutics overview
IQ Therapeutics is a pharmaceutical company which develops antibodies for the prevention and treatment of infectious diseases. The company is headquartered in Groningen, the Netherlands.
For a complete picture of IQ-DAA’s drug-specific PTSR and LoA scores, buy the report here.